Biological Products, (No Diagnostic Substances) · DE · CIK 1991792
Develops and commercializes cretostimogene grenadenorepvec, an immunotherapy for bladder cancer
Comparable business profile · signals at a glance
In the 90 days to Mar 16, 2026: 1 sold $710K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Mulay JamesDirector | Sell | 1,310 | $63.50 | $83K |
| Mar 16, 2026 | Mulay JamesDirector | Sell | 654 | $63.50 | $42K |
| Jan 9, 2026 | Mulay JamesDirector | Sell | 10,491 | $52.99 | $556K |
| Jan 9, 2026 | Mulay JamesDirector | Sell | 654 | $44.16 | $29K |
| Nov 17, 2025 | Post Leonard EDirector | Sell | 1,000 | $41.43 | $41K |
| Oct 13, 2025 | Post Leonard EDirector | Sell | 1,000 | $43.25 | $43K |
| Oct 9, 2025 | Mulay JamesDirector | Sell | 5,903 | $43.99 | $260K |
| Sep 30, 2025 | Post Leonard EDirector | Sell | 5,000 | $40.09 | $200K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.